Every Form 4 that Adial Pharmaceuticals, Inc (ADIL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADIL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADIL filings page.
ADIAL PHARMACEUTICALS, INC. (ADIL) reported that director Wendy B. Young received a grant of stock options for 25,666 shares of common stock on June 12, 2026, at an exercise price of $2.98 per share, expiring June 12, 2036.
The board approved this grant on June 11, 2026, subject to stockholder approval of an increase to the 2017 Equity Incentive Plan, which stockholders provided on September 17, 2026. 2,138 options vested on that approval date, with the remaining 23,528 options vesting in substantially equal installments over 33 months beginning October 12, 2026. No Rule 10b5-1 plan is reported.
Coastlands Capital LP, a 10% owner of ADIAL Pharmaceuticals, reported two open‑market purchases of common stock. It bought 2,000 shares at $2.65 on July 14, 2026 and 1,233 shares at $2.75 on July 16, 2026. Following these trades, Coastlands reported 388,308 shares of ADIL common stock held indirectly, and the related entities disclaim beneficial ownership except to the extent of their pecuniary interests.
Coastlands Capital LP, a ten percent owner of ADIAL PHARMACEUTICALS, INC., reported two open-market purchases of ADIL common stock. On July 9, 2026 it bought 10,053 shares at $2.79 per share, and on July 10, 2026 it bought 1,700 shares at $2.70 per share.
After these transactions, Coastlands Capital LP held 385,075 shares of ADIL common stock, reported as indirect ownership "By Coastlands Capital LP." A joint reporting footnote explains that several related entities and Matthew Perry are filing together and each disclaims beneficial ownership beyond their pecuniary interest.
Adial Pharmaceuticals major holder Coastlands Capital LP reported an open-market purchase of common stock. On this transaction date, an entity associated with Coastlands bought 25,000 Adial shares at $2.60 each, increasing its indirectly held position to 373,322 shares. The filing notes that Coastlands and related entities disclaim beneficial ownership beyond their pecuniary interest in these holdings.
Adial Pharmaceuticals’ Chief Development Officer Matt Davidson reported several acquisitions of company securities tied to the merger with Azora Therapeutics and new equity awards. In the merger, his Azora holdings, including 5,902,500 Azora common shares and preferred shares, were exchanged for Adial common and Series A Non-Voting Convertible Preferred Stock.
He also received 232,417 restricted stock units, each representing one common share, vesting in equal monthly installments over 36 months beginning on July 12, 2026, plus a stock option for 232,417 shares at an exercise price of $2.89 per share, with the same vesting schedule and an expiration date of June 12, 2036. Additional Series A Preferred Stock and common shares are held both directly and through the Matt and Alli Davidson Trust, where he serves as co-trustee.
ADIAL PHARMACEUTICALS, INC. director Wendy B. Young purchased 36,378 Pre-Funded Warrants on June 12, 2026 in an open-market or private transaction at $2.7489 per warrant. Each warrant is exercisable into one share of common stock at an exercise price of $0.001 per share.
The Pre-Funded Warrants have no expiration date and become exercisable after approval of the company’s stockholders. Exercise is limited by a 4.99% beneficial ownership cap, preventing the holder and affiliates from exceeding that ownership level after exercise. Following this transaction, Young directly holds 36,378 Pre-Funded Warrants.
Goodman Tony reported acquisition or exercise transactions in this Form 4 filing.
Adial Pharmaceuticals Chief Operating Officer Tony Goodman received a grant of 26,510 restricted shares of common stock. The award was reported at a price of $0.00 per share, indicating it is a compensation grant rather than an open-market purchase. Following this grant, Goodman directly holds 26,523 common shares. The restricted shares vest in full on the earlier of the one-year anniversary of the April 7, 2026 grant date or a Change of Control under Adial’s 2017 Equity Incentive Plan, as long as he continues serving the company through the vesting date.
ADIAL PHARMACEUTICALS, INC. director Anderson J. Kermit received a grant of stock options covering 9,185 shares of common stock at an exercise price of $1.64 per share. The options expire on April 6, 2036 and fully vest on the earlier of one year from grant or a Change of Control, subject to his continued service. Following this grant, he holds 9,185 options directly.
Schuyler Kevin reported acquisition or exercise transactions in this Form 4 filing.
ADIAL PHARMACEUTICALS, INC. director Kevin Schuyler received a grant of 9,185 shares of common stock as restricted stock compensation. These restricted shares vest in full on the earlier of the one-year anniversary of the grant date or a Change of Control, subject to his continued service. Following the grant, he holds 9,213 common shares directly, plus 4 shares owned by his wife and 230 shares owned by MVA 151 Investors, LLC, which he controls.
Shah Vinay reported acquisition or exercise transactions in this Form 4 filing.
Adial Pharmaceuticals Chief Financial Officer Vinay Shah received an equity award of 17,325 shares of common stock. The shares were granted at no cash cost to him and represent his entire reported direct holding after the transaction. These are restricted shares that vest in full on the earlier of one year from the grant date or a Change of Control under the company’s 2017 Equity Incentive Plan, as long as he continues serving the company through the vesting date.
Gilliland Robertson H. reported acquisition or exercise transactions in this Form 4 filing.
ADIAL PHARMACEUTICALS director receives stock grant
Director Robertson H. Gilliland was awarded 9,185 shares of ADIAL PHARMACEUTICALS common stock as equity compensation. The grant was reported at a price of $0.00 per share, and following this award the director holds 9,185 shares directly.
The shares are restricted and will vest in full on the earlier of one year from the grant date or a Change of Control as defined in the company’s 2017 Equity Incentive Plan, as long as the director continues to serve the company through the vesting date.
Claiborne Cary J reported acquisition or exercise transactions in this Form 4 filing.
Adial Pharmaceuticals Chief Executive Officer Claiborne J. Cary received a grant of 37,985 restricted shares of common stock. The award carries a grant price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
The restricted shares vest in full on the earlier of the one-year anniversary of the grant date or a Change of Control, as defined in Adial’s 2017 Equity Incentive Plan, subject to his continued service through the vesting date. Following this grant, Cary directly holds 40,417 shares of Adial common stock.